Obstetrics and Gynaecology
University of British Columbia Center of Reproductive Health
Gregory Lee completed his Ph. D from California Institute of Technology and postdoctoral studies from University of California, San Diego. He became a full Professor at University of British Columbia in 1989, and retired in 2012 with the title of Professor Emeritus. He is the co-founder of Vancouver BioTech Ltd. He has published more than 200 papers, including 30 papers in cancer research. He has been serving as an editorial board member of the Journal of Carcinogenesis and Mutagenesis, and the Journal of Cancer Science and Therapy since 2012.
Research and Development of Antibody-Based Anti-Cancer Drugs. RP215 monoclonal antibody was shown to recognize specifically a carbohydrate-associated epitope located on the variable regions of cancer cell expressed immunoglobulins, designated in general as CA215.Structural elucidation of carbohydrate-associated epitope in CA215 which is recognized by RP215 monoclonal antibody (Mab). Humanizations of RP215 Mab for preclinical studies. Generations of Rat anti-idiotype Mabs as candidates for the development of anti-cancer vaccines in humans. Establishment of an Anti-GnRH receptor Mab, GHR106, as a substitute of short-acting GnRH analogs for antibody-based anti-cancer drugs, as well as preclinical studies. Elucidation of mechanisms of action for RP215 and GHR106 as antibody-based anti-cancer drugs. Elucidation of a carbohydrate-associated epitope recognized by RP215 monoclonal antibodies.